Endocrinology

New Endocrine Society guidance recommends more individualized evaluation and treatment of central precocious puberty in children.

Researchers detected multiple endocrine-disrupting chemicals in breast milk and infant urine, highlighting early-life exposure during infancy.

The FDA granted accelerated approval to teplizumab (Tzield) for children aged 8–17 with recently diagnosed stage 3 T1D, based on PROTECT phase 3 data.

The integrated CGM, first cleared over-the-counter for adults in 2024, is now available without a prescription for people 2 years of age and older who do not use insulin.

New ADA 2026 analyses show Afrezza delivered comparable glycemic control, favorable safety, and higher treatment satisfaction in youth.

This decision marks the first FDA-approved inhaled insulin for pediatric patients.

An international consensus group has recommended renaming PCOS to PMOS to better reflect the condition’s endocrine and metabolic features.

Two-year data from the pivotal ApproaCH trial showed sustained growth improvements with TransCon CNP in pediatric achondroplasia.

FDA approved insulin glargine-aldy as an interchangeable biosimilar to Lantus for type 1 diabetes and adult type 2 diabetes.

Phase 3 sunRIZE trial of ersodetug in congenital hyperinsulinism missed its primary endpoint but showed CGM-based glycemic gains.

Two-year CAHtalyst data show crinecerfont sustains androgen reduction and lowers glucocorticoid doses in children with congenital adrenal hyperplasia.

FDA expands teplizumab (Tzeld) use to children as young as 1 year with stage 2 type 1 diabetes, aiming to delay progression to clinical disease.

Updated guidance outlines triglyceride thresholds that distinguish ASCVD vs pancreatitis risk and inform targeted management strategies in children.

A first-of-its-kind approval for hypothalamic obesity offers earlier, targeted treatment in children.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

FDA okays once-weekly navepegritide for children with achondroplasia, boosting growth with strong trial data; rollout expected early Q2 2026.

With the priority review, the Prescription Drug User Fee Act date is set for April 29, 2026, for potential approval in this younger indication.

Ferric maltol is now an FDA-approved oral iron therapy for both adults and adolescents with iron deficiency, aged 10 years and older.

Herbert Bravo, MD, and Marian Rewers, MD, PhD, explain how education and coordinated care are key to implementing early screening and treatment for type 1 diabetes.

A peer-to-peer discussion between Herbert Bravo, MD; and Marian Rewers, MD, PhD, examined immune-based treatments that preserved β-cell function and altered disease progression.

Herbert Bravo, MD, and Marian Rewers, MD, PhD, explored how C-peptide preservation reshaped both clinical management and economic considerations in type 1 diabetes.

Clinicians reviewed evidence linking delayed diagnosis of type 1 diabetes to lasting neurologic and metabolic consequences.

Experts discussed how the 3-stage model reframed type 1 diabetes as a condition that could be detected through earlier screening.

This introductory Special Report episode outlines how advances in staging and early detection are reshaping pediatric approaches to type 1 diabetes.

Jonathan Flyer, MD, discusses how the LEAD Pediatric Initiative is addressing persistently low rates of universal pediatric lipid screening.